The Preclinical Research Development program consults with investigators on the scientific information required to support an Investigational New Drug application to FDA. This includes characterization of the product, animals models of safety or efficacy, or toxicology. In addition, the ITHS Preclinical Research Development team will consult on the content of the IND application and FDA interactions in general. This support currently includes review of pre-IND and IND applications.
In some cases it may be advisable to present your program to the Drug and Device Advisory Committee DDAC for preliminary review of the preclinical data supporting the application.
This consultation is limited to four (4) hours and is not charged to the applicants. Future management or oversight of the IND must be built into the funding mechanisms for the program.
Please sign in below to access this form.
Access to this form is restricted to ITHS Members. Please sign in.
Not yet an ITHS member? Members of ITHS are part of a unique catalyst that accelerates discoveries to practice. If you haven't signed up for an ITHS membership yet, learn more and join us.